July 25, 2014 1:46 PM ET

Biotechnology

Company Overview of Sequella, Inc.

Company Overview

Sequella, Inc., a clinical stage biopharmaceutical company, develops and commercializes treatment products for diagnosis and treatment of infectious diseases. The company’s products include TB Patch, a point-of-care diagnostic used to diagnose active tuberculosis (TB) infection; SQ109, a molecule anti-TB drug; drug compliance monitor, a medical device that records when medication is taken; SQ609, an antibiotic compound for vitro and in vivo anti-TB activities; and SQ641, a natural product for the treatment of TB or bacterial pneumonia. Sequella, Inc. was founded in 1997 and is based in Rockville, Maryland.

9610 Medical Center Drive

Suite 200

Rockville, MD 20850

United States

Founded in 1997

Phone:

301-762-7776

Fax:

301-762-7778

Key Executives for Sequella, Inc.

Co-Founder
Age: 66
Co-Founder
Secretary and Director
Executive Vice President of Corporate Development
Vice President of Drug Discovery
Compensation as of Fiscal Year 2014.

Sequella, Inc. Key Developments

Sequella, Inc. Presents at Boston Biotech Conferences LLC's The New York CEO Conference, Nov-13-2013 03:40 PM

Sequella, Inc. Presents at Boston Biotech Conferences LLC's The New York CEO Conference, Nov-13-2013 03:40 PM. Venue: Apella, 450 East 29th Street, New York, NY 10016, United States. Speakers: Carol A. Nacy, Co-Founder, Chairman and Chief Executive Officer.

Sequella Seeks Financing

Sequella, Inc. plans to raise $38 million to pay for clinical trials — almost twice its previous fundraising target. Sequella announced it had snapped up the rights to Pfizer Inc.'s tuberculosis antibiotic, called sutezolid which expands that funding need. "Most big pharma, including Pfizer, are moving out of antibiotics/anti-infective drugs. Small biotech is taking over on the R&D. I think that's very important, because we're facing a crisis in MDR infections worldwide, including in the U.S," said Sequella, Chief Executive Officer, Carol Nacy.

Sequella Inc. Licenses its B-Smart(TM) Technology to Laboratory Corporation of America Holdings

Sequella Inc. licensed its B-SMART(TM) technology to Laboratory Corporation of America(R) Holdings to allow LabCorp to develop a new laboratory-based antibiotic susceptibility assay for Mycobacterium tuberculosis and to commercially use the assay in the United States. The assays that LabCorp will develop using B-SMART(TM) technology will combine nucleic acid testing with phage-based technology to accurately and quickly identify any resistance of M. tuberculosis clinical isolates to antitubercular antibiotics, regardless of whether the resistance genotype is known. Sequella retains all rights to commercialize B-SMART(TM) technology worldwide for indications other than tuberculosis, and for territories other than the United States for tuberculosis.

Similar Private Companies By Industry

Company Name Region
AuraZyme Pharmaceuticals, Inc. United States
Microbes BioSciences, Inc. United States
Alopexx Pharmaceuticals, LLC United States
Stratatech Corporation United States
American Gene Technologies International Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
August 28, 2013
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Sequella, Inc., please visit www.sequella.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.